Muscular Atrophy, Spinal Clinical Trials

7 recruiting

Muscular Atrophy, Spinal Trials at a Glance

7 actively recruiting trials for muscular atrophy, spinal are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 4 with 2 trials, with the heaviest enrollment activity in Norfolk, Philadelphia, and Chicago. Lead sponsors running muscular atrophy, spinal studies include Biogen, Hoffmann-La Roche, and Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Browse muscular atrophy, spinal trials by phase

Treatments under study

About Muscular Atrophy, Spinal Clinical Trials

Looking for clinical trials for Muscular Atrophy, Spinal? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Muscular Atrophy, Spinal trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Muscular Atrophy, Spinal clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 4

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy

Muscular Atrophy, Spinal
Hoffmann-La Roche28 enrolled19 locationsNCT05861999
Recruiting
Phase 2

A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy

Muscular Atrophy, Spinal
Hoffmann-La Roche10 enrolled13 locationsNCT05808764
Recruiting
Phase 4

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy

Muscular Atrophy, Spinal
Hoffmann-La Roche28 enrolled16 locationsNCT05861986
Recruiting
Phase 1

A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)

Muscular Atrophy, Spinal
Biogen58 enrolled19 locationsNCT06555419
Recruiting

A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies

Muscular Atrophy, Spinal
Biogen20 enrolled14 locationsNCT05789758
Recruiting
Phase 3

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

Muscular Atrophy, Spinal
Biogen30 enrolled2 locationsNCT07221669
Recruiting

Natural History of SMA

Muscular Atrophy, Spinal
Fondazione Policlinico Universitario Agostino Gemelli IRCCS1,200 enrolled5 locationsNCT05755451